This work studied the impact of the quorum-sensing molecule, farnesol (FAR), on fluconazole (FLC)-resistant Candida albicans isolate CY 1123 compared with the susceptible standard strain C. albicans SC5314. The genes encoding efflux pumps belonging to the ATP-binding cassette (ABC) and major facilitator superfamilies, together with overexpression or point mutation of the ERG11 gene, are the main resistance mechanisms to azole antifungal drugs.
Results:
The upregulation of genes coding for CDR1, CDR2, and MDR1 were confirmed by qPCR with respect to the housekeeping gene ACT1 in the resistant strain. The contribution of the ERG11 gene was also observed. Markedly, increased pump activity (Cdr1 and/or Cdr2) in the CY 1123 strain was confirmed using diS-C3(3) assay. However, the addition of FAR to the yeasts diminished the difference in staining levels between the SC5314 and CY 1123 strains, demonstrating the concentration-dependent character that could be caused by an effective modulation of Cdr pumps. FAR (60 and 100 μM) was also able to decrease the minimal inhibitory concentrations (MIC50), denoting the inhibition of planktonic cells by 50%, from 8 to 4 μg/mL of FLC when the resistant strain CY 1123 was not cultivated with FLC. However, when it was exposed to 64 μg/mL of FLC, the MIC50 shifted from 64 to 8 μg/mL.
Conclusion:
Besides the many other effects of FAR on eukaryotic and prokaryotic cells, it also affects ABC efflux transporters, resulting in changes in resistance to azoles in C. albicans isolates. However, this effect is dependent on FAR concentrations.
Get full access to this article
View all access options for this article.
References
1.
ArendrupM.C.2013. Candida and candidaemia. Susceptibility and epidemiology. Dan. Med. J. 60:B4698.
2.
El-AziziM., FaragN., and KhardoriN.. 2015. Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model. Ann. Clin. Microbiol. Antimicrob. 14:21.
3.
GuptaV., KohliA., KrishnamurthyS., PuriN., AalamgeerS.A., PanwarS., and PrasadR.. 1998. Identification of polymorphic mutant alleles of CaMDR1, a major facilitator of Candida albicans which confers multidrug resistance, and its in vitro transcriptional activation. Curr. Genet. 34:192–199.
4.
SanglardD., IscherF., ParkinsonT., FalconerD., and BilleJ.. 2003. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob. Agents Chemother. 47:2404–2412.
5.
GulatS., and Doluca DereliM.. 2014. Investigation of the expression levels of efflux pumps in fluconazole-resistant Candida albicans isolates. Mikrobiyol. Bul. 48:325–334.
6.
ZomorodianK., BandeganiA., MirhendiH., PakshirK., AlinejhadN., and Poostforoush FardA.. 2016. In vitro susceptibility and trailing growth effect of clinical isolates of Candida species to azole drugs. Jundishapur. J. Microbiol. 9:e28666.
7.
Schuetzer-MuehlbauerM., WillingerB., EgnerR., EckerG., and KuchlerK.. 2003. Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. Int. J. Antimicrob. Agent. 22:291–300.
8.
PratesR.A., KatoI.T., RibeiroM.S., TegosG.P., and HamblinM.R.. 2011. Influence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of Candida albicans. J. Antimicrob. Chemother. 66:1525–1532.
9.
CannonR.D., LampingE., HolmesA.R., NiimiK., BaretP.V., KeniyaM.V., TanabeK., NiimiM., GoffeauA., and MonkB.C.. 2009. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22:291–321.
10.
HolmesA.R., LinY.H., NiimiK., LampingE., KeniyaM., NiimiM., TanabeK., MonkB.C., and CannonR.D.. 2008. ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob. Agents Chemother. 52:3851–3862.
11.
PrasadR., SharmaM., and RawalM.K.. 2011. Functionally relevant residues of Cdr1p: a multidrug ABC transporter of human pathogenic Candida albicans. J. Amino Acids. 2011:531412.
12.
ShaoJ., ZhangM., WangT., LiY., and WangC.. 2015. The roles of CDR1, CDR2, and MDR1 in kaempferol-induced suppression with fluconazole-resistant Candida albicans. Pharm. Biol. 12:1–9.
13.
NagayoshiY., MiyazakiT., ShimamuraS., NakayamaH., MinematsuA., YamauchiS., TakazonoT., NakamuraS., YanagiharaK., KohnoS., MukaeH., and IzumikawaK.. 2017. Unexpected effects of azole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species. PLoS One, 12:e0180990.
14.
LiY., WanZ., LiuW., and LiR.. 2015. Synergistic activity of chloroquine with fluconazole against fluconazole-resistant isolates of Candida species. Antimicrob. Agents Chemother. 59:1365–1369.
15.
GraceM.H.2002. Chemical composition and biological activity of the volatiles of Anthemis melampodina and Pluchea dioscoridis. Phytother Res. 16:183–185.
16.
WeberK., SohrR., SchulzB., FleischhackerM., and RuhnkeM.. 2008. Secretion of E,E-farnesol and biofilm formation in eight different Candida species. Antimicrob. Agents Chemother. 52:1859–1861.
17.
HornbyJ.M., JensenE.C., LisecA.D., TastoJ.J., JahnkeB., ShoemakerR., DussaultP., and NickersonK.W.. 2001. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl. Environ. Microbiol. 67:2982–2992.
18.
PolkeM., and JacobsenI.D.. 2017. Quorum sensing by farnesol revisited. Curr. Genet. 63:791–797.
19.
RamageG., SavilleS.P., WickesB.L., and López-RibotJ.L.. 2002. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl. Environ. Microbiol. 68:5459–5463.
20.
YuL.H., WeiX., MaM., ChenX.J., and XuS.B.. 2012. Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm. Antimicrob. Agents Chemother. 56:770–775.
21.
DerengowskiL.S., De-Souza-SilvaC., BrazS.V., Mello-De-SousaT.M., BáoS.N., KyawC.M., and Silva-PereiraI.. 2009. Antimicrobial effect of farnesol, a Candida albicans quorum sensing molecule, on Paracoccidioides brasiliensis growth and morphogenesis. Ann. Clin. Microbiol. Antimicrob. 8:13.
22.
BraschJ., HorterF., FritschD., Beck-JendroschekV., TrögerA., and FranckeW.. 2014. Acyclic sesquiterpenes released by Candida albicans inhibit growth of dermatophytes. Med. Mycol. 52:46–55.
23.
KatragkouA., McCarthyM., AlexanderE.L., AntachopoulosC., MeletiadisJ., Jabra-RizkM.A., PetraitisV., RoilidesE., and WalshT.J.. 2015. In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. J. Antimicrob. Chemother. 70:470–478.
24.
SharmaM., and PrasadR.. 2011. The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans. Antimicrob. Agents Chemother. 55:4834–4843.
25.
CordeiroR.A., TeixeiraC.E., BrilhanteR.S., Castelo-BrancoD.S., PaivaM.A., Giffoni LeiteJ.J., LimaD.T., MonteiroA.J., SidrimJ.J., and RochaM.F.. 2013. Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol. Med. Mycol. 51:53–59.
26.
Jabra-RizkM.A., ShirtliffM., JamesC., and MeillerT.. 2006. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance. FEMS. Yeast Res. 6:1063–1073.
27.
GillumA.M., TsayE.Y., and KirschD.R.. 1984. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol. Gen. Genet. 198:179–182.
28.
TamuraM., WatanabeK., MikamiY., YazawaK., and NishimuraK.. 2001. Molecular characterization of new clinical isolates of Candida albicans and C. dubliniensis in Japan: analysis reveals a new genotype of C. albicans with group I intron. J. Clin. Microbiol. 39:4309–4315.
29.
Černáková, DižováL., S., and BujdákováH.. 2017. Employment of methylene blue irradiated with laser light source in photodynamic inactivation of biofilm formed by Candida albicans strain resistant to fluconazole. Med. Mycol. 55:748–753.
30.
EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0, valid from 2015-11-16. Available at www.eucast.org.
31.
Čadek, ChládkováR., K., SiglerK., and GáškováD.. 2004. Impact of the growth phase on the activity of multidrug resistance pumps and membrane potential of S. cerevisiae: effect of pump overproduction and carbon source. Biochim. Biophys. Acta. 1665:111–117.
32.
HendrychT., KodedováM., SiglerK., and GáškováD.. 2009. Characterization of the kinetics and mechanisms of inhibition of drugs interacting with the S. cerevisiae multidrug resistance pumps Pdr5p and Snq2p. Biochim. Biophys. Acta. 1788:717–723.
33.
SzczepaniakJ., M. Łukaszewicz, and KrasowskaA.. 2015. Detection of inhibitors of Candida albicans Cdr transporters using a diS-C3(3) fluorescence. Front. Microbiol. 6:1–6.
34.
DenksteinováB., GáškováD., HeřmanP., VečeřJ., MalínskýJ., PlášekJ., and SiglerK.. 1997. Monitoring of membrane potential changes in S. cerevisiae by diS-C3(3) fluorescence. Folia. Microbiol. (Praha). 42:221–224.
35.
GáškováD., BrodskáB., HermanP., VecerJ., MalínskýJ., SiglerK., BenadaO., and PlásekJ.. 1998. Fluorescent probing of membrane potential inwalled cells: diS-C3(3) assay in Saccharomyces cerevisiae. Yeast, 14:1189–1197.
36.
DawisM.A., IsenbergH.D., FranceK.A., and JenkinsS.G.2003. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. Antimicrob. Chemother. 51:1203–1211.
37.
OddsF.C.2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
SpampinatoC., and LeonardiD.. 2013. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed. Res. Int. 2013:204237.
40.
CartledgeJ.D., MidgleyJ., and GazzardB.G.. 1997. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. AIDS. 11:1839–1844.
41.
MuluA., KassuA., AnagawB., MogesB., GelawA., AlemayehuM., BelyhunY., BiadglegneF., HurissaZ., MogesF., and IsogaiE.. 2013. Frequent detection of “azole” resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC. Infect. Dis. 13:82.
42.
ManeA., VidhateP., KusroC., WamanV., SaxenaV., Kulkarni-KaleU., and RisbudA.. 2016. Molecular mechanisms associated with Fluconazole resistance in clinical Candida albicans isolates from India. Mycoses. 59:93–100.
43.
GauthierC., WeberS., AlarcoA.M., AlqawiO., DaoudR., GeorgesE., and RaymondM.. 2003. Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters. Antimicrob. Agents Chemother. 47:1543–1554.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
